CORDA Investment Management LLC. Has $51.43 Million Position in Merck & Co., Inc. $MRK

Key Points

• CORDA Investment Management trimmed its Merck stake by 2.2% in the first quarter but still held 427,526 shares worth about $51.4 million, making Merck its sixth-largest position.
• Merck received a major regulatory boost as the FDA approved KEYTRUDA and KEYTRUDA QLEX with Padcev for certain muscle-invasive bladder cancer patients before and after surgery, potentially expanding the company’s oncology sales.
• Wall Street remains cautiously upbeat: analysts have a consensus Moderate Buy rating with a $132.72 target, while Merck also reported better-than-expected quarterly revenue and earnings and continues paying a 2.7% dividend yield.

CORDA Investment Management LLC. lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 427,526 shares of the company's stock after selling 9,548 shares during the quarter. Merck & Co., Inc. accounts for 3.6% of CORDA Investment Management LLC.'s portfolio, making the stock its 6th biggest holding. CORDA Investment Management LLC.'s holdings in Merck & Co., Inc. were worth $51,427,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Chesapeake Wealth Management boosted its stake in shares of Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after purchasing an additional 87 shares during the period. South Plains Financial Inc. raised its stake in shares of Merck & Co., Inc. by 0.6% during the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company's stock valued at $1,635,000 after acquiring an additional 89 shares in the last quarter. Syverson Strege & Co boosted its holdings in shares of Merck & Co., Inc. by 2.2% in the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock valued at $436,000 after purchasing an additional 90 shares during the period. Nations Financial Group Inc. IA ADV lifted its holdings in shares of Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company's stock worth $2,819,000 after buying an additional 91 shares during the period. Finally, Westside Investment Management Inc. lifted its stake in Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock worth $331,000 after acquiring an additional 93 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Wall Street Analysts Forecast Growth

A number of research firms have commented on MRK. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. CICC Research started coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price objective on the stock. UBS Group upped their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research note on Thursday. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and a consensus target price of $132.72.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $123.72 on Monday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company's fifty day moving average price is $118.83 and its 200-day moving average price is $116.36. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $130.29. The firm has a market capitalization of $305.56 billion, a PE ratio of 34.85, a price-to-earnings-growth ratio of 2.65 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm's quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.